<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="17" ids="39025">HDL</z:chebi> protects against <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> development </plain></SENT>
<SENT sid="1" pm="."><plain>Defective functioning of <z:chebi fb="17" ids="39025">HDL</z:chebi> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> may be one cause of increased <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="17" ids="39025">HDL</z:chebi> modulates <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidation through the action of paraoxonase-1 (PON1), which is one of the major mechanisms by which <z:chebi fb="17" ids="39025">HDL</z:chebi> is antiatherogenic </plain></SENT>
<SENT sid="3" pm="."><plain>We have compared the ability of <z:chebi fb="17" ids="39025">HDL</z:chebi> from people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 36) with no <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> (CHD) to metabolize oxidized palmitoyl <z:chebi fb="0" ids="22612">arachidonyl</z:chebi> <z:chebi fb="0" ids="49183">phosphatidylcholine</z:chebi> (ox-PAPC), a major product of <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidation and a PON1 substrate, with that of <z:chebi fb="17" ids="39025">HDL</z:chebi> isolated from healthy control subjects (n = 19) and people with CHD but no <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 37) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="17" ids="39025">HDL</z:chebi> from people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> metabolized 11% less ox-PAPC, and <z:chebi fb="17" ids="39025">HDL</z:chebi> from people with CHD metabolized 6% less, compared with <z:chebi fb="17" ids="39025">HDL</z:chebi> from control subjects (both P &lt; 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>The ability of <z:chebi fb="17" ids="39025">HDL</z:chebi> from control and type 2 diabetic subjects containing the PON1-192RR alloform to metabolize ox-PAPC was significantly reduced compared with PON1-192QQ or QR genotypes (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>The defective ability of <z:chebi fb="17" ids="39025">HDL</z:chebi> to metabolize ox-PAPC was reflected in a significant increase in circulating plasma oxidized <z:chebi fb="15" ids="39026">LDL</z:chebi> concentration in the two patient groups (37 +/- 5, 53 +/- 7, and 65 +/- 7 mmol/l for control, CHD, and type 2 diabetic subjects, respectively; P &lt; 0.001), with PON1-192RR genotype carriers having the highest concentrations </plain></SENT>
<SENT sid="7" pm="."><plain>In the control group, there was a significant negative correlation between serum PON1 activity and oxidized <z:chebi fb="15" ids="39026">LDL</z:chebi> concentration (r = 0.856, P &lt; 0.001); however, this correlation was not evident in the patient groups </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="17" ids="39025">HDL</z:chebi> from type 2 diabetic subjects without CHD had a decreased ability to metabolize oxidized <z:chebi fb="1" ids="16247">phospholipids</z:chebi>, which could lead to increased susceptibility to develop <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
</text></document>